Allogene Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Allogene Therapeutics generated cash of -$237,733,000, which is less than the previous year. Cash used in financing activities reached the amount of $95,695,000 last year. Net change in cash is therefore $21,251,000.
Cash Flow
| 2017 | 0 | 0 | 0 |
|---|---|---|---|
| 2018 | -44.65M | -632.79M | 771.18M |
| 2019 | -137.35M | 164.08M | 58.96M |
| 2020 | -115.09M | -505.12M | 633.59M |
| 2021 | -184.81M | 163.65M | 11.96M |
| 2022 | -220.51M | 106.15M | 2.95M |
| 2023 | -237.73M | 163.28M | 95.69M |
ALLO Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 72.19M | 183.60M | 192.8M | 179.42M | 93.73M | 0 | 0 |
Operating activities | |||||||
Net income | -327.26M | -332.63M | -257.00M | -250.22M | -184.59M | -211.50M | -24K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 14.19M | 14.29M | 10.45M | 7.58M | 5.02M | 1.5M | 0 |
Stock-based compensation expense | 65.95M | 83.6M | 80.81M | 65.26M | 46.06M | 0 | 0 |
| Deferred income tax benefit | 65.95M | 83.6M | 80.81M | 65.26M | 46.06M | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -7.50M | 4.86M | -767K | 615K | -985K | 8.8M | 0 |
Cash generated by operating activities | -237.73M | -220.51M | -184.81M | -115.09M | -137.35M | -44.65M | 0 |
Investing activities | |||||||
Purchases Of Investments | -438.62M | -248.10M | -525.58M | -1.03B | -252.62M | -649.30M | 0 |
Investments In Property Plant And Equipment | -1.51M | -5.19M | -21.44M | -65.95M | -50.79M | -3.23M | 0 |
Acquisitions Net | 0 | -111.35M | -17.71M | 439.16M | -5.07M | 0 | 0 |
Cash generated by investing activities | 163.28M | 106.15M | 163.65M | -505.12M | 164.08M | -632.79M | 0 |
Financing activities | |||||||
Common Stock Issued | 91.11M | 2.95M | 11.96M | 621.93M | 54.21M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 2.46M | 0 | 2.84M | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 95.69M | 2.95M | 11.96M | 633.59M | 58.96M | 771.18M | 0 |
Net Change In Cash | 21.25M | -111.41M | -9.19M | 13.37M | 85.69M | 93.73M | 0 |
Cash at end of period | 93.44M | 72.19M | 183.60M | 192.8M | 179.42M | 93.73M | 0 |
| Data source | Data source | Data source | Data source | Data source | Data source |